Table 1.
Characteristics of participants
| Cisplatin | Oxaliplatin | |
| Gender (m/f) | 13 m/7 f | 20 m/5 f |
| Age at time of follow-up (median) | 49 years | 64 years |
| Duration of follow-up | 18–75 months (median 41) | 8–33 months (median 18) |
| Tumour type | Testicular carcinoma (9) | Colorectal carcinoma (25) |
| Yolk sac carcinoma (1) | ||
| Non small cell lung cancer (1) | ||
| Small cell lung cancer (1) | ||
| Head and neck carcinoma (8) | ||
| Cumulative dose | 300–600 mg/m2 cisplatin (median 350) | 585–1170 mg/m2 oxaliplatin (median 878) |
| 195–390 mg/m2 Pt | 287–575 mg/m2 Pt | |
| (median 227) | (median 431) | |
| Sodium thiosulfate | 5 head and neck carcinoma patients treated intra-arterially with 600 mg/m2 cisplatin | NA |
| Ca/Mg infusion | NA | 24/25 |
| GSTM1 | 8/20 positive, 12/20 negative | 10/25 positive, 15/25 negative |
| GSTT1 | 17/20 wildtype, 3/20 negative | 21/25 positive, 4/25 negative |
| GSTP1 | 12/20105Ile/105Ile-GSTP1 | 9/25105Ile/105Ile-GSTP1 |
| 7/20105Val/105Ile-GSTP1 | 10/25105Val/105Ile-GSTP1 | |
| 1/20105Val/105Val-GSTP1 | 6/25105Val/105Val-GSTP1 |
NA = not applicable